<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>69(9)</volume><submitter>Ji S</submitter><pubmed_abstract>&lt;h4>Introduction&lt;/h4>Alzheimer's disease (AD) is a major public health concern worldwide, but there are still no drugs available that treat it effectively. Previous studies have shown that phenylethanoid glycosides have pharmacological effects, which include anti-AD properties, but the underlying mechanisms by which they ameliorate AD symptoms remain unknown.&lt;h4>Methods&lt;/h4>In this study, we used an APP/PS1 AD mouse model to explore the function and mechanisms underlying savatiside A (SA) and torenoside B (TB) in the treatment of AD. SA or TB (100 mg·kg-1·d-1) was orally administered to 7-month-old APP/PS1 mice for 4 weeks. Cognitive and memory functions were measured using behavioral experiments (including the Morris water maze test and the Y-maze spontaneous alternation test). Molecular </pubmed_abstract><journal>Gerontology</journal><pagination>1065-1075</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10568609</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice.</pubmed_title><pmcid>PMC10568609</pmcid><pubmed_authors>Jiang Y</pubmed_authors><pubmed_authors>Ji S</pubmed_authors><pubmed_authors>Yu L</pubmed_authors><pubmed_authors>Ma X</pubmed_authors><pubmed_authors>Guo D</pubmed_authors><pubmed_authors>Huang L</pubmed_authors><pubmed_authors>Zhu R</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Novel Phenylethanoid Glycosides Improve Hippocampal Synaptic Plasticity via the Cyclic Adenosine Monophosphate-CREB-Brain-Derived Neurotrophic Growth Factor Pathway in APP/PS1 Transgenic Mice.</name><description>&lt;h4>Introduction&lt;/h4>Alzheimer's disease (AD) is a major public health concern worldwide, but there are still no drugs available that treat it effectively. Previous studies have shown that phenylethanoid glycosides have pharmacological effects, which include anti-AD properties, but the underlying mechanisms by which they ameliorate AD symptoms remain unknown.&lt;h4>Methods&lt;/h4>In this study, we used an APP/PS1 AD mouse model to explore the function and mechanisms underlying savatiside A (SA) and torenoside B (TB) in the treatment of AD. SA or TB (100 mg·kg-1·d-1) was orally administered to 7-month-old APP/PS1 mice for 4 weeks. Cognitive and memory functions were measured using behavioral experiments (including the Morris water maze test and the Y-maze spontaneous alternation test). Molecular </description><dates><release>2023-01-01T00:00:00Z</release><publication>2023</publication><modification>2025-04-05T11:54:10.909Z</modification><creation>2025-04-05T11:54:10.909Z</creation></dates><accession>S-EPMC10568609</accession><cross_references><pubmed>37285833</pubmed><doi>10.1159/000531194</doi></cross_references></HashMap>